Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. März 2025 05:31 ET | Quelle: Research and Markets

2025 Endothelin Receptor Antagonist Pipeline Insights for 10+ Companies and 15+ Pipeline Drugs, Including Zibotentan (AstraZeneca), SC0062 (Biocity Biopharmaceutics), and GMA301 (Gmax Biopharm)

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Endothelin Receptor Antagonist - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides...
30. Januar 2024 04:56 ET | Quelle: Research and Markets

Global Branded PAH Therapeutics Market Set to Reach $9.86 Billion by 2029: Analysis by Drug Class, Route of Administration, Distribution Channel, Region and Country

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global Branded PAH Therapeutics Market (2023 Edition) - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country:...
03. Februar 2023 04:58 ET | Quelle: Research and Markets

Insights on the Pulmonary Arterial Hypertension (PAH) Drugs Global Market to 2027: Increasing Prevalence of Cardiovascular and Pulmonary Disorders Drives Growth

Dublin, Feb. 03, 2023 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been...
01. Dezember 2020 05:18 ET | Quelle: Research and Markets

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2020: Increasing Awareness Regarding Available Treatment Alternatives to Drive Market Growth

Dublin, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been...